Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma
Masayuki Kurokawa,
Sei Naito,
Tomoyuki Kato,
Masaki Ushijima,
Atsushi Yamagishi,
Toshihiko Sakurai,
Hayato Nishida,
Norihiko Tsuchiya
Affiliations
Masayuki Kurokawa
Corresponding author.; Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
Sei Naito
Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
Tomoyuki Kato
Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
Masaki Ushijima
Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
Atsushi Yamagishi
Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
Toshihiko Sakurai
Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
Hayato Nishida
Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
Norihiko Tsuchiya
Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
